Peter Altevogt

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5217897/publications.pdf

Version: 2024-02-01

137 papers	14,860 citations	18482 62 h-index	19190 118 g-index
138 all docs	138 docs citations	138 times ranked	18046 citing authors

#	Article	IF	Citations
1	Vesiclepedia: A Compendium for Extracellular Vesicles with Continuous Community Annotation. PLoS Biology, 2012, 10, e1001450.	5.6	1,064
2	Exosomes: From biogenesis and secretion to biological function. Immunology Letters, 2006, 107, 102-108.	2.5	775
3	Body fluid derived exosomes as a novel template for clinical diagnostics. Journal of Translational Medicine, 2011, 9, 86.	4.4	612
4	Interaction and uptake of exosomes by ovarian cancer cells. BMC Cancer, 2011, 11, 108.	2.6	513
5	Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression. British Journal of Cancer, 2019, 120, 16-25.	6.4	504
6	Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors. Frontiers in Immunology, 2018, 9, 1310.	4.8	404
7	Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. Journal of Cell Biology, 2001, 155, 661-674.	5.2	357
8	L1, a novel target of Î²-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. Journal of Cell Biology, 2005, 168, 633-642.	5.2	335
9	Malignant ascites-derived exosomes of ovarian carcinoma patients contain CD24 and EpCAM. Gynecologic Oncology, 2007, 107, 563-571.	1.4	335
10	Extracellular Vesicle-Mediated Transfer of Genetic Information between the Hematopoietic System and the Brain in Response to Inflammation. PLoS Biology, 2014, 12, e1001874.	5.6	312
11	CD24, a Mucin-Type Glycoprotein, Is a Ligand for P-Selectin on Human Tumor Cells. Blood, 1997, 89, 3385-3395.	1.4	293
12	Systemic presence and tumor-growth promoting effect of ovarian carcinoma released exosomes. Cancer Letters, 2009, 278, 73-81.	7.2	265
13	CD24 mediates rolling of breast carcinoma cells on Pâ€selectin. FASEB Journal, 1998, 12, 1241-1251.	0.5	258
14	L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet, The, 2003, 362, 869-875.	13.7	252
15	Loss of EpCAM expression in breast cancer derived serum exosomes: Role of proteolytic cleavage. Gynecologic Oncology, 2011, 122, 437-446.	1.4	248
16	Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment. OncoImmunology, 2015, 4, e1008371.	4.6	227
17	A role for exosomes in the constitutive and stimulus-induced ectodomain cleavage of L1 and CD44. Biochemical Journal, 2006, 393, 609-618.	3.7	217
18	CD24 expression is a new prognostic marker in breast cancer. Clinical Cancer Research, 2003, 9, 4906-13.	7.0	213

#	Article	IF	Citations
19	L1 Is Sequentially Processed by Two Differently Activated Metalloproteases and Presenilin/Î³-Secretase and Regulates Neural Cell Adhesion, Cell Migration, and Neurite Outgrowth. Molecular and Cellular Biology, 2005, 25, 9040-9053.	2.3	212
20	Body Fluid Exosomes Promote Secretion of Inflammatory Cytokines in Monocytic Cells via Toll-like Receptor Signaling. Journal of Biological Chemistry, 2013, 288, 36691-36702.	3.4	203
21	Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neuroscience Letters, 2007, 428, 43-46.	2.1	200
22	ADAM10â€mediated cleavage of L1 adhesion molecule at the cell surface and in released membrane vesicles. FASEB Journal, 2003, 17, 292-294.	0.5	199
23	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. Journal of Clinical Investigation, 2018, 128, 5505-5516.	8.2	193
24	SOX2 in development and cancer biology. Seminars in Cancer Biology, 2020, 67, 74-82.	9.6	186
25	L1CAM in Early-Stage Type I Endometrial Cancer: Results of a Large Multicenter Evaluation. Journal of the National Cancer Institute, 2013, 105, 1142-1150.	6.3	185
26	Cleavage of L1 in Exosomes and Apoptotic Membrane Vesicles Released from Ovarian Carcinoma Cells. Clinical Cancer Research, 2005, 11, 2492-2501.	7.0	174
27	CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. Journal of Cell Science, 2006, 119, 314-325.	2.0	170
28	Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cellâ€"Activating Receptor NKp30. Cancer Research, 2014, 74, 3429-3440.	0.9	169
29	L1CAM. Cell Adhesion and Migration, 2012, 6, 374-384.	2.7	168
30	Role of Src Kinases in the ADAM-mediated Release of L1 Adhesion Molecule from Human Tumor Cells. Journal of Biological Chemistry, 2000, 275, 15490-15497.	3.4	163
31	Integrin Leukocyte Function-associated Antigen-1-mediated Cell Binding Can Be Activated by Clustering of Membrane Rafts. Journal of Biological Chemistry, 1999, 274, 36921-36927.	3.4	154
32	<scp>L1CAM</scp> in human cancer. International Journal of Cancer, 2016, 138, 1565-1576.	5.1	148
33	Cytoplasmic CD24 Expression in Colorectal Cancer Independently Correlates with Shortened Patient Survival. Clinical Cancer Research, 2005, 11, 6574-6581.	7.0	145
34	IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy. Cellular Immunology, 2021, 359, 104254.	3.0	141
35	Efficient Inhibition of Intra-Peritoneal Tumor Growth and Dissemination of Human Ovarian Carcinoma Cells in Nude Mice by Anti-L1-Cell Adhesion Molecule Monoclonal Antibody Treatment. Cancer Research, 2006, 66, 936-943.	0.9	140
36	Targeting CD24 for Treatment of Colorectal and Pancreatic Cancer by Monoclonal Antibodies or Small Interfering RNA. Cancer Research, 2008, 68, 2803-2812.	0.9	140

#	Article	IF	Citations
37	CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions. Cancer Research, 2018, 78, 157-167.	0.9	127
38	L1CAM malfunction in the nervous system and human carcinomas. Cellular and Molecular Life Sciences, 2010, 67, 2425-2437.	5.4	122
39	Heat-stable antigen (CD24) as ligand for mouse P-selectin. International Immunology, 1994, 6, 1027-1036.	4.0	110
40	L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. Cancer Letters, 2003, 189, 237-247.	7.2	108
41	Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloproteaseâ€dependent ectodomain shedding and exosome secretion. Journal of Cellular Biochemistry, 2008, 103, 1783-1797.	2.6	104
42	L1 adhesion molecule on human lymphocytes and monocytes: expression and involvement in binding to Î±vÎ²3 integrin. European Journal of Immunology, 1996, 26, 2508-2516.	2.9	103
43	Novel insights into the function of <scp>CD24</scp>: A driving force in cancer. International Journal of Cancer, 2021, 148, 546-559.	5.1	100
44	Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling. Cancer Research, 2019, 79, 4715-4728.	0.9	97
45	CD24 is a marker for human breast carcinoma. Cancer Letters, 1999, 143, 87-94.	7.2	92
46	Up-regulation of L1CAM in Pancreatic Duct Cells Is Transforming Growth Factor Î²1â€“ and Slug-Dependent: Role in Malignant Transformation of Pancreatic Cancer. Cancer Research, 2009, 69, 4517-4526.	0.9	90
47	Upâ€regulation of L1CAM is linked to loss of hormone receptors and Eâ€cadherin in aggressive subtypes of endometrial carcinomas. Journal of Pathology, 2010, 220, 551-561.	4.5	90
48	Nuclear translocation and signalling of L1-CAM in human carcinoma cells requires ADAM10 and presenilin/Î³-secretase activity. Biochemical Journal, 2009, 420, 391-402.	3.7	89
49	The adhesion molecule L1 (CD171) promotes melanoma progression. International Journal of Cancer, 2006, 119, 549-555.	5.1	87
50	L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecologic Oncology, 2007, 104, 461-469.	1.4	83
51	Heat-stable antigen/CD24 on mouse T lymphocytes: evidence for a costimulatory function. European Journal of Immunology, 1994, 24, 731-737.	2.9	82
52	L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer. Molecular Cancer, 2011, 10, 127.	19.2	82
53	Redirected T Cells That Target Pancreatic Adenocarcinoma Antigens Eliminate Tumors and Metastases in Mice. Gastroenterology, 2012, 143, 1375-1384.e5.	1.3	82
54	EMT-associated up-regulation of L1CAM provides insights into L1CAM-mediated integrin signalling and NF-ÎºB activation. Carcinogenesis, 2012, 33, 1919-1929.	2.8	75

#	Article	IF	Citations
55	CD24 induces localization of Î²1 integrin to lipid raft domains. Biochemical and Biophysical Research Communications, 2008, 365, 35-41.	2.1	74
56	Copper-67 Radioimmunotherapy and Growth Inhibition by Antiâ€“L1-Cell Adhesion Molecule Monoclonal Antibodies in a Therapy Model of Ovarian Cancer Metastasis. Clinical Cancer Research, 2007, 13, 603-611.	7.0	73
57	Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapyâ˜†. Human Pathology, 2006, 37, 1000-1008.	2.0	72
58	Integrin and Neurocan Binding to L1 Involves Distinct Ig Domains. Journal of Biological Chemistry, 1999, 274, 24602-24610.	3.4	69
59	CD24 controls Src/STAT3 activity in human tumors. Cellular and Molecular Life Sciences, 2012, 69, 3863-3879.	5.4	69
60	Functional role of N-glycosylation from ADAM10 in processing, localization and activity of the enzyme. Biochimica Et Biophysica Acta - General Subjects, 2008, 1780, 905-913.	2.4	68
61	SOX2â€mediated upregulation of CD24 promotes adaptive resistance toward targeted therapy in melanoma. International Journal of Cancer, 2018, 143, 3131-3142.	5.1	66
62	N-Glycosylation of total cellular glycoproteins from the human ovarian carcinoma SKOV3 cell line and of recombinantly expressed human erythropoietin. Glycobiology, 2011, 21, 376-386.	2.5	65
63	Contractile Forces Contribute to Increased Glycosylphosphatidylinositol-anchored Receptor CD24-facilitated Cancer Cell Invasion. Journal of Biological Chemistry, 2011, 286, 34858-34871.	3.4	65
64	L1 augments cell migration and tumor growth but not Î²3 integrin expression in ovarian carcinomas. International Journal of Cancer, 2005, 115, 658-665.	5.1	64
65	Extracellular Vesicles from Ovarian Carcinoma Cells Display Specific Glycosignatures. Biomolecules, 2015, 5, 1741-1761.	4.0	64
66	Novel insights into exosome-induced, tumor-associated inflammation and immunomodulation. Seminars in Cancer Biology, 2014, 28, 51-57.	9.6	63
67	Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget, 2014, 5, 462-472.	1.8	63
68	Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Laboratory Investigation, 2010, 90, 1102-1116.	3.7	62
69	Therapeutic Antibodies to Human L1CAM: Functional Characterization and Application in a Mouse Model for Ovarian Carcinoma. Cancer Research, 2010, 70, 2504-2515.	0.9	62
70	Exosomes as a Potential Tool for a Specific Delivery of Functional Molecules. Methods in Molecular Biology, 2013, 1049, 495-511.	0.9	61
71	Targeting SOX2 in anticancer therapy. Expert Opinion on Therapeutic Targets, 2018, 22, 983-991.	3.4	60
72	Expression and function of the neural cell adhesion molecule L1 in mouse leukocytes. European Journal of Immunology, 1992, 22, 1199-1205.	2.9	59

#	Article	IF	Citations
73	IL-6 regulates CCR5 expression and immunosuppressive capacity of MDSC in murine melanoma. , 2020, 8, e000949.		59
74	Evidence forCisInteraction and Cooperative Signalling by the Heat-stable Antigen Nectadrin (murine) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 993-1004.	2.6	57
75	The cell adhesion molecule L1: species- and cell-type-dependent multiple binding mechanisms. Differentiation, 1997, 61, 143-150.	1.9	54
76	Linking L1CAM-mediated signaling to NF-Î¹B activation. Trends in Molecular Medicine, 2011, 17, 178-187.	6.7	51
77	Mouse CD24 as a Signaling Molecule for Integrin-Mediated Cell Binding: Functional and Physical Association with src-Kinases. Biochemical and Biophysical Research Communications, 1997, 234, 330-334.	2.1	50
78	Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. BBA - Proteins and Proteomics, 1997, 1337, 287-294.	2.1	50
79	CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clinical and Experimental Metastasis, 2012, 29, 27-38.	3.3	50
80	Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Letters, 2012, 319, 66-82.	7.2	49
81	Blockade of natural killer cell-mediated lysis by NCAM140 expressed on tumor cells. International Journal of Cancer, 2007, 120, 2625-2634.	5.1	45
82	L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. Cancer Letters, 2006, 239, 212-226.	7.2	44
83	Expression of CD24 and Siglec-10 in first trimester placenta: implications for immune tolerance at the fetalâ€“maternal interface. Histochemistry and Cell Biology, 2017, 147, 565-574.	1.7	42
84	Expression and prognostic value of L1-CAM in breast cancer. Oncology Reports, 2009, 22, 1109-17.	2.6	41
85	L1 adhesion molecule on mouse leukocytes: regulation and involvement in endothelial cell binding. European Journal of Immunology, 1993, 23, 2927-2931.	2.9	39
86	Characterization of the L1-Neurocan-binding Site. Journal of Biological Chemistry, 2000, 275, 34478-34485.	3.4	39
87	miR-21-3p is a positive regulator of L1CAM in several human carcinomas. Cancer Letters, 2014, 354, 455-466.	7.2	39
88	L1CAM is expressed in triple-negative breast cancers and is inversely correlated with Androgen receptor. BMC Cancer, 2014, 14, 958.	2.6	38
89	Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT. International Journal of Cancer, 2015, 136, E326-39.	5.1	37
90	Enhanced L1CAM expression on pancreatic tumor endothelium mediates selective tumor cell transmigration. Journal of Molecular Medicine, 2009, 87, 99-112.	3.9	35

#	Article	IF	Citations
91	Combined targeting of TGF-Î²1 and integrin Î²3 impairs lymph node metastasis in a mouse model of non-small-cell lung cancer. Molecular Cancer, 2014, 13, 112.	19.2	35
92	L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. BMC Molecular Biology, 2010, 11, 64.	3.0	34
93	L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Molecular Oncology, 2014, 8, 982-997.	4.6	34
94	Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma. International Journal of Molecular Sciences, 2020, 21, 2367.	4.1	34
95	The L1 Adhesion Molecule Supports Î±vÎ²3-Mediated Migration of Human Tumor Cells and Activated T Lymphocytes. Biochemical and Biophysical Research Communications, 1997, 232, 236-239.	2.1	33
96	Identification and Characterization of Tumor-Initiating Cells in Multiple Myeloma. Journal of the National Cancer Institute, 2020, 112, 507-515.	6.3	33
97	Adhesion molecules CD171 (L1CAM) and CD24 are expressed by primary neuroendocrine carcinomas of the skin (Merkel cell carcinomas). Journal of Cutaneous Pathology, 2003, 30, 363-368.	1.3	32
98	The RGD integrin binding site in human L1-CAM is important for nuclear signaling. Experimental Cell Research, 2008, 314, 2411-2418.	2.6	31
99	L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma. Pathology and Oncology Research, 2016, 22, 863-868.	1.9	31
100	Transfer of T Cell Surface Molecules to Dendritic Cells upon CD4+ T Cell Priming Involves Two Distinct Mechanisms. Journal of Immunology, 2008, 181, 3965-3973.	0.8	29
101	Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma. Oncology Reports, 2010, 24, 909-15.	2.6	28
102	The effects of anti-CD2 antibodies on the differentiation of mouse thymocytes. European Journal of Immunology, 1989, 19, 951-954.	2.9	26
103	A role for the VLA-4 integrin in the activation of human memory B cells. European Journal of Immunology, 1997, 27, 2757-2764.	2.9	26
104	Antibodies directed against L1-CAM synergize with Genistein in inhibiting growth and survival pathways in SKOV3ip human ovarian cancer cells. Cancer Letters, 2008, 261, 193-204.	7.2	25
105	TMPRSS2:ERGgene fusion variants induce TGF-Î² signaling and epithelial to mesenchymal transition in human prostate cancer cells. Oncotarget, 2017, 8, 25115-25130.	1.8	23
106	Procoagulant extracellular vesicles in amniotic fluid. Translational Research, 2017, 184, 12-20.e1.	5.0	22
107	Single-Molecule Localization Microscopy allows for the analysis of cancer metastasis-specific miRNA distribution on the nanoscale. Oncotarget, 2015, 6, 44745-44757.	1.8	22
108	CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Research and Treatment, 2012, 132, 819-831.	2.5	21

#	Article	IF	Citations
109	STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice. , 2022, 10, e004384.		21
110	Role of L1 cell adhesion molecule (L1CAM) in the metastatic cascade: promotion of dissemination, colonization, and metastatic growth. Clinical and Experimental Metastasis, 2014, 31, 87-100.	3.3	20
111	CD24 polymorphisms in breast cancer: impact on prognosis and risk. Breast Cancer Research and Treatment, 2013, 137, 927-937.	2.5	19
112	Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis, 2012, 33, 84-93.	2.8	18
113	Influence of L1-CAM expression of breast cancer cells on adhesion to endothelial cells. Journal of Cancer Research and Clinical Oncology, 2013, 139, 107-121.	2.5	18
114	Full-Length L1CAM and Not Its Î”27 Splice Variant Promotes Metastasis through Induction of Gelatinase Expression. PLoS ONE, 2011, 6, e18989.	2.5	18
115	Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. International Journal of Oncology, 2006, 28, 551.	3.3	17
116	Recent insights into the role of <scp>L1CAM</scp> in cancer initiation and progression. International Journal of Cancer, 2020, 147, 3292-3296.	5.1	17
117	Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients. BMC Clinical Pathology, 2015, 15, 19.	1.8	16
118	Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancerâ€“testis (CT-X) antigens. BMC Cancer, 2013, 13, 156.	2.6	15
119	A novel method for measuring cellular antibody uptake using imaging flow cytometry reveals distinct uptake rates for two different monoclonal antibodies targeting L1. Journal of Immunological Methods, 2015, 423, 70-77.	1.4	15
120	L1 (CD171) as a novel biomarker for ovarian and endometrial carcinomas. Expert Review of Molecular Diagnostics, 2004, 4, 455-462.	3.1	14
121	Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-Î²1 (TGF-Î²)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. International Journal of Oncology, 2011, 38, 257-66.	3.9	12
122	L1 Cell Adhesion Molecule as a Potential Therapeutic Target in Murine Models of Endometriosis Using a Monoclonal Antibody Approach. PLoS ONE, 2013, 8, e82512.	2.5	11
123	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions. Clinical Cancer Research, 2015, 21, 1010-1018.	7.0	11
124	CD2: a functional adhesion molecule on murine B cells, involved in interleukin-4-induced aggregation. European Journal of Immunology, 1993, 23, 888-892.	2.9	10
125	Inhibition of cell proliferation, adhesion, and invasion with an anti-L1-cell adhesion molecule monoclonal antibody in an in vitro endometriosis model. Fertility and Sterility, 2010, 94, 1102-1104.	1.0	9
126	Glycoconjugate expression in adenoid cystic carcinoma of the salivary glands: upâ€regulation of L1 predicts fatal prognosis. Histopathology, 2011, 59, 299-307.	2.9	9

#	Article	IF	Citations
127	A Standardized Staining Protocol for L1CAM on Formalin-Fixed, Paraffin-Embedded Tissues Using Automated Platforms. International Journal of Biological Markers, 2014, 29, 180-183.	1.8	9
128	L1CAM in the Early Enteric and Urogenital System. Journal of Histochemistry and Cytochemistry, 2017, 65, 21-32.	2.5	9
129	Evaluating L1CAM expression in human endometrial cancer using qRT-PCR. Oncotarget, 2016, 7, 40221-40232.	1.8	9
130	Critical amino acid residues of the ?4 subunit for ?4?7 integrin function. Journal of Cellular Biochemistry, 2001, 83, 304-319.	2.6	8
131	Role of STAT3 dependent SOX2 and CD24 expression in melanoma cell adaptive resistance towards targeted therapies. Oncotarget, 2019, 10, 1662-1663.	1.8	7
132	HER3-Receptor-Mediated STAT3 Activation Plays a Central Role in Adaptive Resistance toward Vemurafenib in Melanoma. Cancers, 2020, 12, 3761.	3.7	7
133	DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer. American Journal of Pathology, 2021, 191, 618-630.	3.8	7
134	Reduced Placental CD24 in Preterm Preeclampsia Is an Indicator for a Failure of Immune Tolerance. International Journal of Molecular Sciences, 2021, 22, 8045.	4.1	7
135	miR-449a Repression Leads to Enhanced NOTCH Signaling in TMPRSS2:ERG Fusion Positive Prostate Cancer Cells. Cancers, 2021, 13, 964.	3.7	5
136	Lack of CD24 expression in mice reduces the number of leukocytes in the colon. Immunology Letters, 2014, 161, 140-148.	2.5	4
137	L1-CAM is commonly expressed in testicular germ cell tumours. Journal of Clinical Pathology, 2016, 69, 460-462.	2.0	3